Search Results - "Antrilli, Thomas M."

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis by Hennan, James K, Elokdah, Hassan, Leal, Mauricio, Ji, Allena, Friedrichs, Gregory S, Morgan, Gwen A, Swillo, Robert E, Antrilli, Thomas M, Hreha, Amy, Crandall, David L

“…We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a canine model of electrolytic injury. Dogs received by oral gavage…”
Get more information

Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities by Jurica, Elizabeth A., Wu, Ximao, Williams, Kristin N., Haque, Lauren E., Rampulla, Richard A., Mathur, Arvind, Zhou, Min, Cao, Gary, Cai, Hong, Wang, Tao, Liu, Heng, Xu, Carrie, Kunselman, Lori K., Antrilli, Thomas M., Hicks, Michael B., Sun, Qin, Dierks, Elizabeth A., Apedo, Atsu, Moore, Douglas B., Foster, Kimberly A., Cvijic, Mary Ellen, Panemangalore, Reshma, Khandelwal, Purnima, Wilkes, Jason J., Zinker, Bradley A., Robertson, Donald G., Janovitz, Evan B., Galella, Michael, Li, Yi-Xin, Li, Julia, Ramar, Thangeswaran, Jalagam, Prasada Rao, Jayaram, Ramya, Whaley, Jean M., Barrish, Joel C., Robl, Jeffrey A., Ewing, William R., Ellsworth, Bruce A.

“…[Display omitted] GPR40 AgoPAMs are highly effective antidiabetic agents that have a dual mechanism of action, stimulating both glucose-dependent insulin and…”
Get full text

Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1 by Hu, Baihua, Jetter, James W., Wrobel, Jay E., Antrilli, Thomas M., Bauer, Jean S., Di, Li, Polakowski, Sergiusz, Jain, Uday, Crandall, David L.

“…[Display omitted] We synthesized and evaluated a novel series of 2-carboxylic acid indole-based inhibitors of plasminogen activator inhibitor-1 (PAI-1)…”
Get full text

Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1 by Gopalsamy, Ariamala, Kincaid, Scott L., Ellingboe, John W., Groeling, Thomas M., Antrilli, Thomas M., Krishnamurthy, Girija, Aulabaugh, Ann, Friedrichs, Gregory S., Crandall, David L.

“…Graphic A novel series of PAI-1 inhibitors containing an oxadiazolidinedione moiety were identified by high through-put screening. Optimization of substituents…”
Get full text

Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists by Crombie, Aimee L., Antrilli, Thomas M., Campbell, Brandon A., Crandall, David L., Failli, Amedeo A., He, Yanan, Kern, Jeffrey C., Moore, William J., Nogle, Lisa M., Trybulski, Eugene J.

“…A series of biaryl amides containing an azabicyclo[3.2.1]octane amine headpiece were synthesized and evaluated as mixed arginine vasopressin (AVP) receptor…”
Get full text

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation by Crandall, David L, Hennan, James K, Elokdah, Hassan, Krishnamurthy, Girija, Antrilli, Thomas M, Bauer, Jean S, Morgan, Gwen A, Swillo, Robert E

“…Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of tissue plasminogen activator (tPA) and is elevated in diseases of vascular…”
Get full text

Release of PAI-1 by Human Preadipocytes and Adipocytes Independent of Insulin and IGF-1 by Crandall, David L., Groeling, Thomas M., Busler, Dennis E., Antrilli, Thomas M.

“…The effect of insulin and insulin-like growth factor-1 (IGF-1) on plasminogen activator inhibitor-1 (PAI-1) release from primary cultures of human…”
Get full text